CLDX — Celldex Therapeutics, Inc.

Summary of Celldex Therapeutics Q4 2021 Earnings Call

1. Key Financial Results and Metrics

• Celldex Therapeutics ended 2021 with $408 million in cash, providing a runway through 2025.
• The company reported a strong year in 2021, with positive clinical data across its programs and a successful follow-on offering that bolstered its balance sheet.

2. Strategic Updates and Business Highlights

• CDX-0159, the lead candidate, showed promising results in Phase 1 trials for chronic inducible urticaria (CIU), with a 95% complete response rate and 100% overall response rate after a single dose.
• The company initiated two additional studies for CDX-0159, including a Phase 1 healthy volunteer study for a subcutaneous formulation, which demonstrated a favorable safety profile and pharmacokinetic properties.
• Positive interim data from a six-month chronic toxicology study in nonhuman primates supports the upcoming Phase 2 trials in chronic spontaneous urticaria (CSU) and CIU, set to begin in Q2 2022.
• Expansion into a fourth indication, eosinophilic esophagitis (EoE), is planned for Q4 2022, highlighting the potential of CDX-0159 as a mast cell depleting agent.

3. Forward Guidance and Outlook

• The Phase 2 studies for CSU and CIU are on track to initiate in Q2 2022.
• Data from the Phase 1 multiple ascending dose IV study in CSU is expected to be presented at the EAACI 2022 meeting in July.
• The company aims to explore additional indications for CDX-0159 based on emerging data and patient needs.

4. Bad News, Challenges, or Points of Concern

• There were concerns regarding the impact of CDX-0159 on spermatogenesis in nonhuman primates, which is a known effect of KIT inhibition. However, the company noted that this effect is reversible and not expected at therapeutic doses in humans.
• The company faces challenges in patient recruitment for the cholinergic urticaria cohort due to difficulties in identifying appropriate patients.
• Competitive pressures exist in the urticaria treatment landscape, with multiple products targeting similar pathways, though management emphasized the unique mechanism of CDX-0159.

5. Notable Q&A Insights

• Management confirmed that patients refractory to biologic therapy will be included in the Phase 1b study for CSU.
• The Phase 1b data from the 4.5 mg cohort will not be required to initiate the Phase 2 studies, as compelling data from the 3 mg cohort is deemed sufficient.
• The relationship between mast cells and eosinophils in EoE was discussed, with evidence suggesting that mast cells may influence eosinophil infiltration, supporting the rationale for CDX-0159 in this indication.
• The company is working on tech transfer for CDX-0159 to a contract manufacturing organization to optimize and scale up production for late-stage trials.

Overall, Celldex Therapeutics appears well-positioned for growth in 2022, with a strong financial foundation and promising clinical data, despite facing some challenges related to patient recruitment and competitive pressures.